ACCESS Trial for Lupus Nephritis, Part 2
Part 2: Participating in the ACCESS Trial A brief overview of what you can expect if you are considering participating in the ACCESS clinical trial for lupus nephritis. The ACCESS trial is sponsored by the National Institutes of Health and conducted by the Immune Tolerance Network at clinical centers throughout the US.
Video Rating: 5 / 5
C4d on Circulating Cells and Renal Tissue as Markers of Lupus Nephritis
The kidneys will be affected in approximately one-third of all cases with lupus. Diagnosing and monitoring lupus-related kidney disease, called lupus nephritis, often requires an invasive kidney biopsy. Dr. Amy Kao of the Allegheny-Singer Research Institute in Pittsburgh, has conducted a study, supported by the Lupus Foundation of America, on evaluation of CD4 molecules on T-cells as a possible marker for lupus nephritis. Validating such a biomarker for this potentially life-threatening complication of lupus would eliminate or greatly reduce the need for kidney biopsies. In this video, Dr. Kao discusses her study and future steps for this line of investigation.
Orignal From: ACCESS Trial for Lupus Nephritis, Part 2
No comments:
Post a Comment